Related Experiment Videos

Cost considerations in cancer chemotherapy

M H Tattersall, M L Friedlander

Australian Health Review : a Publication of the Australian Hospital Association

|April 11, 1982

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

Gynecologic oncology·2019

Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.

Familial cancer·2017

Patient-reported outcomes in ovarian cancer clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2013

Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.

Breast cancer research and treatment·2011

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.

Familial cancer·2011

See all related articles